Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.

Abstract: Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.

Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.

Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.

Abstract: Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.

Abstract: Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.

Abstract: The present invention relates to biomimetic scaffolds, methods for making the same, and methods for using the same. The scaffolds comprise a plurality of graded or tapered microchannels that provide spatial control for cell penetration. The scaffolds are useful for regenerating missing interface tissue between two adjacent tissues, or regeneration and integration of two adjacent tissues directly.

Abstract: The present invention relates to compositions comprising ionic compounds surrounded by organic matrices, and methods for producing such compositions. In various embodiments, the compositions of the present invention are co-crystals of an organic compound and a salt. The organic compound forms matrices with channel structures, wherein the organic matrices interact relatively poorly with the salt, thus allowing for excellent ion mobility through the channel structures. In one embodiment, the compositions are soft-solid electrolytes, comprising ions such as lithium or sodium, which can be used in batteries or other electrochemical devices. The electrolyte compositions of the present invention exhibit relatively high ionic conductivities with a negligible activation barrier for ion migration, i.e., the compositions exhibit barrierless ion conduction. In addition, the compositions exhibit good conductivities at very low temperatures, making them useful in a variety of low temperature applications.

Abstract: A tactile sensor, computer readable medium, methods of using and manufacturing the tactile sensor, and methods and apparatuses for processing the information generated by the tactile sensor. The tactile sensor includes a planar optical waveguide comprised of a flexible and transparent layer; a light configured to direct light into the optical waveguide; a light sensor or an imager facing the optical waveguide and configured to generate signals from light scattered out of the optical waveguide; and a controller which may be configured to generate an image of the object and characteristics of the object. The waveguide may be configured so that some of the light directed into the optical waveguide is scattered out of the waveguide if the waveguide is deformed by being pressed against the object. A finite element and a neural network are used to estimate mechanical characteristics of the objects.

Abstract: The present application provides an external thermionic cathode distributed x-ray apparatus, including a vacuum box which is sealed at its periphery, where the interior thereof is high vacuum; a plurality of electron transmitting units arranged in a linear array and installed on the side wall of the vacuum box, where each electron transmitting unit is independent to each other; an anode installed in the center inside the vacuum box, where in the direction of length, the anode is parallel to the orientation of the electron transmitting unit, and in the direction of width, the anode has a predetermined angle with respect to the plane of the electron transmitting unit; a power supply and control system having a high voltage power supply and a focusing power supply; and a transmitting control means and a control system.

Abstract: The dynamic positioning of sensors, which exploit the mechanical and physiological changes in tissues, can significantly increase the performance in characterization of tumors. Here, we disclose the Optical Dynamic Imaging (ODI) System for tumor characterization. ODI System estimates size, depth, elastic modulus and optical properties of embedded objects. The ODI System consists of a tactile imaging sensor (TIS), and a near infrared diffuse spectral imaging. To obtain mechanical properties of the target, we compress the region of interest with the probe, then the light from the probe is scattered and captured by the camera as a tactile image. On the other hand, using a light source and the camera as a detector, we obtain the diffuse spectral images. From these images, we compute the absorption coefficient of the embedded tumor phantom. We move the source-detector simultaneously and collect optical information. We termed this maneuver as dynamic positioning.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Abstract: The present disclosure provides an antimicrobial composition including a compound which is a biscationic or triscationic amphiphile, and the method of making such an antimicrobial composition, and the method of using such a compound or composition for antimicrobial use. The antimicrobial composition can include a compound having the formula (I) wherein R is a methylene group unsubstituted or optionally substituted, s is an integer in the range from 1 to 6, R1, R2, R3 or R4 is H or a C1-4 alkyl unsubstituted or optionally substituted, X is a halogen, m and n are integers in the range from 5 to 25, and m is not equal to n. Alternatively, the antimicrobial composition can comprise a compound having the formula (III) or (IV) wherein R1, R2, R3, R4 R5, or R6 is H or a C1-4 alkyl unsubstituted or optionally substituted, X or Y is a halogen, and m and n are integers in the range from 5 to 25.